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Susceptibility of outer hair 
cells to cholesterol chelator 
2-hydroxypropyl-β-cyclodextrine is 
prestin-dependent
Satoe Takahashi1, Kazuaki Homma1,3, Yingjie Zhou2, Shinichi Nishimura4,5, Chongwen Duan1, 
Jessie Chen1, Aisha Ahmad2, Mary Ann Cheatham2,3 & Jing Zheng1,3
Niemann-Pick type C1 disease (NPC1) is a fatal genetic disorder caused by impaired intracellular 
cholesterol trafficking. Recent studies reported ototoxicity of 2-hydroxypropyl- β-cyclodextrin 
(HPβCD), a cholesterol chelator and the only promising treatment for NPC1. Because outer hair cells 
(OHCs) are the only cochlear cells affected by HPβCD, we investigated whether prestin, an OHC-specific 
motor protein, might be involved. Single, high-dose administration of HPβCD resulted in OHC death in 
prestin wildtype (WT) mice whereas OHCs were largely spared in prestin knockout (KO) mice in the basal 
region, implicating prestin’s involvement in ototoxicity of HPβCD. We found that prestin can interact 
with cholesterol in vitro, suggesting that HPβCD-induced ototoxicity may involve disruption of this 
interaction. Time-lapse analysis revealed that OHCs isolated from WT animals rapidly deteriorated upon 
HPβCD treatment while those from prestin-KOs tolerated the same regimen. These results suggest that 
a prestin-dependent mechanism contributes to HPβCD ototoxicity.
Cholesterol is an essential component of the eukaryotic plasma membrane, which plays important roles in many 
physiological processes. Alterations of cholesterol levels can modify physical properties of the cell membrane 
such as thickness and fluidity, thereby affecting various membrane proteins1. In addition, direct binding of cho-
lesterol to membrane proteins is reported to have functional importance2. Signal transduction through lipid-raft 
formation also depends on the cholesterol content of the membrane3. One of the commonly used methods for 
membrane cholesterol manipulation is the use of cyclodextrins (CDs)4, a family of cyclic oligosaccharides consist-
ing of α -D-glucopyranose molecules joined in a ring form. CDs can complex with hydrophobic molecules such 
as cholesterol through their hydrophobic core and enhance their solubility via their hydrophilic outer surface. 
Because of this amphipathic nature, CDs are widely used in a variety of applications in the food and pharmaceu-
tical industries from mobilization of cholesterol to drug delivery5.
Recently, 2-hydroxypropyl-β -cyclodextrin (HPβ CD) has attracted particular interest, as it was demonstrated 
to alleviate the cholesterol transport deficiency in cells isolated from Niemann-Pick disease type C1 (NPC1) 
patients6. NPC1 is a rare genetic disorder characterized by a failure to traffic intracellular cholesterol and lipids, 
causing progressive neural degeneration and early death in affected individuals7. Although studies in NPC1 ani-
mal models established the effectiveness of HPβ CD8,9, the compound is unfortunately ototoxic10 even in human 
NPC1 patients11,12. Recent studies have reported that HPβ CD-treated mouse cochleae exhibited loss of outer 
hair cells (OHCs), but not other cells in the organ of Corti (OC) or in other major organ systems regardless of 
the mode of administration10,13. These observations suggest that OHCs are particularly vulnerable to cholesterol 
extraction by HPβ CD, and that an OHC-specific mechanism may underlie the ototoxicity.
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OHCs are sensory cells specialized for cochlear amplification, which mediates sensitivity and sharp frequency 
selectivity in mammals14. Prestin, an OHC-specific molecular motor protein, is required for this active mechani-
cal amplification function15,16. Although prestin belongs to a diverse anion transporter family, solute carrier pro-
tein 26 (SLC26), it (SLC26A5) is the only member that confers so-called electromotility on cells17. It is estimated 
that 60–75% of the OHC’s lateral wall surface area is packed with ~11 nm particles, which are presumed to be 
comprised of prestin tetramers18,19. As a membrane protein, prestin’s function is significantly modulated by cho-
lesterol manipulation20–22. It is generally thought that cholesterol’s effect on prestin is indirect and occurs by alter-
ing the physical properties of the lateral membrane (LM) where prestin resides, similar to numerous factors that 
change lipid membrane properties including membrane tension, temperature, and lipid thickness23–27. However, 
it is not clear why OHCs are more vulnerable to HPβ CD as compared to other cells in the OC.
In this study, we sought to understand critical determinants that mediate OHC death caused by HPβ CD 
treatment. We identified prestin, an OHC-specific motor protein, as an important factor that influences OHC fate 
in response to HPβ CD. Using an in vitro system, we determined that prestin is capable of binding to cholesterol, 
which implies that cholesterol depletion by HPβ CD may interfere with this interaction. Consistent with this idea, 
application of HPβ CD on isolated OHCs or OCs resulted in rapid cell shrinking and occasional rupture, indi-
cating that the membrane is compromised. Interestingly, sense organs from prestin-KO mice resisted the same 
HPβ CD treatment. Taken together, our results underscore the potential contribution of prestin to the toxic effects 
of cholesterol depletion, which needs to be considered when employing combinatorial therapeutic strategies 
using HPβ CD in NPC1 patients.
Results
Prestin-dependent susceptibility of OHCs to HPβCD treatment. Since OHCs were the only cells 
lost after HPβ CD treatment10, and since cholesterol manipulation modulates the function of the OHC-specific 
protein, prestin21, we reasoned that prestin may be involved in HPβ CD-induced OHC loss. WT and prestin-KO 
littermates28 were, therefore, treated in parallel with the high dose of HPβ CD (8000 mg/kg) previously shown to 
cause hearing loss10. We confirmed that HPβ CD-treated WT cochleae examined 7 days post treatment exhibited 
massive OHC loss (Fig. 1a). Interestingly, HPβ CD treatment of prestin-KO mice resulted in a similar loss of 
OHCs in the apical region but OHCs in the mid-to-basal regions were largely preserved (Fig. 1b,c). Inner hair 
cells (IHCs) and other supporting cell types in the OC were unaffected by the treatment in all the animals tested, 
confirming that the toxic effect of HPβ CD is limited to OHCs as previously reported10 (Supplemental Fig. 1). 
Representative images in Fig. 1d,e highlight the differential toxicity of HPβ CD between WT and prestin-KO 
mice, which is independent of genetic background. Similar patterns of OHC loss/preservation were observed in 
both FVB and 129/B6 strains (WT n = 10 and KO n = 8). Closer examination of HPβ CD-treated OCs from WT 
animals revealed condensed nuclear staining and fragmented membrane staining in WT OHCs as early as at 
8 hours post injection (Fig. 1f,g). Some OHC loss was also evident in prestin-KO cochleae at this time, indicating 
that the action of HPβ CD is rather fast (Fig. 1f,g).
We also measured cochlear function before and 7–8 days post treatment. As expected, both distortion product 
otoacoustic emissions (DPOAE) and auditory brain stem responses (ABR) were significantly impaired by HPβ CD 
treatment in WT mice. In vivo physiological measurements showed loss of DPOAEs for equal level primaries at 
70 dB SPL at all f2 frequencies (Fig. 2a) and increased ABR thresholds at 32 kHz (Fig. 2b) on the order of 40–50 dB. 
This change in phenotype is consistent with loss of OHC function. Anatomical examination of the HPβ CD-treated 
WT mice showed massive OHC loss, but other cell types including IHCs and supporting cells remained intact 
(Fig. 1 and Supplemental Fig. 1). Because untreated prestin-KO mice lack OHC electromotility and show large 
reductions in neural responses28,29, HPβ CD treatment had a minimal effect on DPOAEs and ABRs in mice lacking 
prestin (Fig. 2a,b) due to the loss of cochlear amplification. Only in one prestin-KO were DPOAEs measured at 70 dB 
and these responses for low f2 frequencies were lost after treatment. The observation that WT mice after HPβ CD 
injection exhibited ABR thresholds similar to prestin KOs before treatment is consistent with the anatomical data 
showing preservation of IHCs and supporting cells in WT controls following cholesterol manipulation. If IHCs and/
or spiral ganglion neurons had also been severely affected, a further loss of sensitivity would have been anticipated. 
Taken together, the data suggest that prestin is one of the mediators of OHC loss caused by HPβ CD treatment.
Prestin-dependent distribution of cholesterol in the OHC membrane. β − cyclodextrins are known 
to extract cholesterol from the plasma membrane30,31. Since OHCs from prestin-KO animals tolerated HPβ CD 
treatment (Fig. 1), we wondered whether cholesterol distribution differed between OHCs with or without prestin. 
The cholesterol content of the OHC’s lateral membrane (LM) is low based on filipin staining, a polyene antifungal 
that binds to a 3β -hydroxyl group of cholesterol4,20,21,32. Because of its fluorescent nature, filipin is commonly used 
to detect cholesterol. However, it is not very stable and photobleaches rapidly. In order to reevaluate the cholesterol 
distribution in the inner ear with and without prestin, we utilized a cholesterol-binding small molecule, theonel-
lamide (TNM). TNM was originally isolated from a marine sponge, and has been reported to bind in a specific 
manner33,34 to the same 3β -hydroxyl group of cholesterol as does filipin. Staining patterns in WT mice using 
fluorescein-conjugated TNM (TNM-FL)35 were consistent with previous observations using filipin: high levels 
of staining are seen at the apical and basal regions of each OHC, while the lateral walls where prestin resides are 
not stained regardless of the position of OHCs within the cochlea (Fig. 3a,b). Although OHCs in prestin-KOs are 
~40% shorter than WT28,36,37, the TNM-FL staining revealed that cholesterol was present in the LM as well as in 
apical and basal regions (Fig. 3c). This cholesterol-staining pattern in mice lacking prestin is evident in the apical 
half of cochlea, but not in the base probably because the cells become short, which reduces the LM dramatically. In 
contrast to WT OHCs, other polarized cells in the OC, such as IHCs and supporting cells, are also evenly stained 
by TNM-FL regardless of position (Supplemental Figs 1 and 2). No noticeable reduction of TNM-FL staining was 
observed 7 days post treatment independent of whether prestin was expressed or not10 (Supplemental Fig. 2). 
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Thus, OHCs that express prestin have an uneven cholesterol distribution, which appears to be absent in OHCs that 
lack prestin and in other cell types in the OC, suggesting a unique relationship between prestin and cholesterol.
Interaction of prestin and cholesterol. Prestin is essential for OHC electromotility, structural integrity, 
and survival15,28,37,38. Previous studies have described a variety of cholesterol effects on prestin regulation, includ-
ing its membrane targeting, oligomerization, and lipid-raft association21,39,40, as well as its voltage-dependent 
motor function20,41. These effects can be attributed to changes in physical properties of the biological membrane 
and/or to direct functional modulation through specific binding41. Although OHCs are highly susceptible to 
HPβ CD, filipin and TMN did not stain the prestin-containing LM of OHCs. This observation raises the pos-
sibility that filipin and TMN may not access cholesterol when it is already in a complex with prestin and/or 
other proteins in the LM. In fact, it has been reported that some cholesterol-containing membranes are not 
labeled by filipin42–44. Therefore, we tested whether prestin can directly and specifically interact with cholesterol 
in vitro. Using cholesterol-coupled affinity beads45,46, we performed a pull-down assay with YFP-tagged pres-
tin heterologously expressed in a stable HEK cell line47. Although a trace amount of prestin protein was pulled 
down by cholesterol-conjugated beads, the majority of prestin molecules did not bind to the cholesterol beads 
(Supplementary Fig. 3). We reasoned that prestin may have already been in a complex with cholesterol in the 
stable HEK cell line, making it difficult to interact with the cholesterol beads.
In order to better observe an association between cholesterol and prestin, we turned to an Sf9 insect cell 
line with known low-cholesterol content (10–20 times less) compared to mammalian cells30,48, and established a 
stable cell line that expresses GFP-tagged WT-prestin. The resulting sf9-prestin-GFP cells express prestin-GFP 
at the plasma membrane (Fig. 4a). Consistent with the presence of functional prestin molecules at this location, 
Figure 1. OHC loss in WT exceeds that in prestin-KO mice after HPβCD treatment. (a,b) WT and 
prestin-KO mice from a het x het breeder pair on the FVB background were treated with either saline or 
8000 mg/kg HPβ CD at P20–21. OHC survival was determined 7 days post injection. Thin lines represent the 
results from individual animals while thick lines are the average of each treatment (WT saline, n = 2; WT 
HPβ CD n = 3; KO saline, n = 3; HPβ CD, n = 3). OHC loss in the mid-to-basal region is observed in all WT 
cochleae, while OHCs were better preserved in KO cochleae. The dashed line indicates the boundary between 
apex and mid-base used in (c–e). (c) OHC survival is significant in mid-to-basal regions of HPβ CD-treated 
prestin-KO cochlea. Mean ± SD are plotted, and significance determined using one-way ANOVA with Tukey’s 
post analysis. n.s., not significant; ***p ≤ 0.001. (d,e) Representative images of saline or HPβ CD-treated cochleae 
from WT (d) and prestin-KO (e) animals at apex and mid-base. Anti-oncomodulin (OCM) antibody was used 
to stain OHCs, and phalloidin-Alexa 546 for actin. Scale bars, 100 μ m. (f,g) WT mice on the FVB background 
were treated with 8000 mg/kg HPβ CD at P21 for 8 hours, and their cochleae harvested for immunofluorescence. 
The whole mount OC sections were stained with anti-prestin (WT) or anti-oncomodulin (KO) antibodies, 
Phalloidin-Alexa 546, and Hoechst 33342 for OHCs, actin, and nuclei, respectively. (f) Representative images 
of HPβ CD-treated cochleae from WT (top panels) and prestin-KO (bottom panels) at the apex. Early events 
of OHC loss were observed for both WT and KO. For WT, fragmented OHCs were seen (judged by smooth vs. 
punctate prestin staining). For prestin-KO, absence of OCM staining indicates OHC loss. (g) Representative 
images of HPβ CD-treated cochleae from prestin-WT and KO at the mid-base region of the cochlea. No intact 
OHCs were present in WT (left panels), although condensed nuclei indicating dying cells were observed. OHCs 
are largely intact in KO mice (right panels). Scale bars, 20 μ m.
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sf9-prestin-GFP cells exhibit nonlinear capacitance (NLC), a signature of prestin’s motor activity49,50. The NLC 
of sf9-prestin-GFP cells responded to cholesterol loading and depletion in qualitatively the same manner as pre-
viously reported for isolated OHCs and prestin-expressing HEK293 cells21,22 (Fig. 4b–e). Vpkcm is a parameter 
that describes the optimal voltage operating point of prestin while alpha represents prestin’s voltage sensitiv-
ity. Significant hyperpolarization of Vpkcm and reduction in alpha were observed under the cholesterol loading 
condition, suggesting that cholesterol affects the voltage operating point and sensitivity of prestin, respectively 
(Fig. 4c,d). Because of the low cholesterol content in Sf9 cells compared to other mammalian cell types, depolariza-
tion in Vpkcm in response to cholesterol depletion was minimal as expected (Fig. 4b,c). Similarly, cholesterol loading 
resulted in aggregation of prestin in Sf9-prestin-WT cells as previously described in HEK cells21, while cholesterol 
depletion did not affect the prestin’s distribution (Fig. 4f). Charge density, which correlates the density of the amount 
of functional prestin molecules at the PM, was not affected by acute cholesterol manipulations (Fig. 4e). Using 
Sf9-prestin-GFP cells, we also were able to recapitulate prestin’s interaction with cholesterol-beads in the pull-down 
assay. Prestin-GFP was pulled-down with cholesterol beads but not with unconjugated control beads as shown in 
Fig. 4g. Band intensities were measured and compared for control vs. cholesterol beads as in lanes 1 and 2, (Student’s 
t-test, p = 0.0059, n = 5). Addition of exogenous free cholesterol abolished prestin-GFP binding, indicating that 
this interaction is specific (Fig. 4g, lane 3). These data suggest a direct interaction of prestin and cholesterol in vitro.
OHCs isolated from Prestin-KOs tolerate HPβCD treatment. Because of the close relationship 
between prestin and cholesterol, depletion of cholesterol may compromise the stability of the prestin-enriched 
LM, resulting in HPβ CD-induced OHC death. In fact, Rajagopalan and colleagues noted “a drastic morpholog-
ical change in OHCs and even cell death” while treating isolated OHCs with methyl-β -cyclodextrin (Mβ CD), 
which has a higher binding affinity to cholesterol than HPβ CD21,51. We also observed rapid shortening of isolated 
WT OHCs and morphological changes in the OC upon addition of 1 mM HPβ CD, a concentration commonly 
used in cell culture media (Fig. 5a and Supplemental Movie 1). At a higher HPβ CD concentration (10 mM), we 
noticed OHC “rupture” in OC explants from WT animals where OHC nuclei seemed to suddenly (within one 
frame of a 4 sec interval) increase in size and then shrink (Fig. 5b, red asterisks and Supplemental Movie 2). 
Interestingly, the OHC “rupture” events were not evident in prestin-KO mice during a comparable duration 
of time-lapse recordings. Although there appeared to be some gradual increase in OHC size over time (in ~4 
frames in a 4 sec interval, white asterisks), sudden “rupture” as seen in WT OCs was largely absent (Fig. 5c and 
Supplemental Movie 3). Thus, our in vitro observations corroborate the in vivo OHC survival data (see Fig. 1), i.e., 
prestin-KO OHCs tolerate the same HPβ CD treatment that damages WT OHCs. These observations suggest that 
the extraction of cholesterol by HPβ CD results in rapid membrane disruption of OHCs in a prestin-dependent 
manner, leading to cell death.
Figure 2. In vivo physiology of HPβCD-treated WT- and prestin-KO mice. (a) Distortion product 
otoacoustic emissions (DPOAEs) for WT and prestin-KO mice (n = 4 each) on the FVB background were 
recorded for L1 = L2 = 70 dB SPL before (“Pre”) and 7 days after (“Post”) 8000 mg/kg HPβ CD treatment as in 
Fig. 1. HPβ CD treatment abolishes DPOAEs in WT mice (faint red traces). Because prestin-KO mice (black 
traces) already have reduced emissions (Liberman et al., 2002), HPβ CD did not affect DPOAEs in these mice 
as dramatically as in controls. (b) Auditory brainstem responses (ABR) from the same WT and prestin-KO 
mice as in (a) were determined using a 32 kHz tone burst before (“Pre”) and after (“Post”) HPβ CD treatment. 
HPβ CD treatment significantly increased the ABR threshold in WT mice. Prestin-KO mice already have a large 
threshold shift (Liberman et al., 2002) so that HPβ CD did not affect ABR thresholds in these mice. Mean ± SD 
are plotted; significance was determined using an unpaired t-test. n.s., not significant; ***p ≤ 0.0001.
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Discussion
In this study, we identified prestin as a contributor to HPβ CD ototoxicity. Single, high-dose administration of 
HPβ CD resulted in massive OHC loss in WT mice whereas OHCs were preserved in prestin-KO mice, indicat-
ing that prestin is involved (Fig. 1). Prestin localizes to the LM of OHCs, a specialized domain that undergoes 
voltage-dependent length and stiffness changes16,28,52. It is also known that the cholesterol content of the OHC’s 
LM is low when measured using filipin20,21,32 or TNM-FL (Fig. 3). Nevertheless, the LM must contain cholesterol 
as significant functional modulation of prestin can be seen in isolated OHCs using a cholesterol-depleting proce-
dure21. Regardless of the abundance of cholesterol in the LM, it is clear that OHCs are sensitive to perturbation by 
HPβ CD, as the toxic effect of HPβ CD is rapid and limited to OHCs (Fig. 5a,b, and Supplemental Movies 1 and 2). 
Although our data show that prestin can interact with cholesterol in vitro (Fig. 4g), the identification of cholesterol 
binding motifs in prestin is required in order to determine whether disruption of the cholesterol-prestin interac-
tion plays a role in OHC death. Yamashita et al. recently suggested that the OHC’s trilaminate structure, which 
consists of PM, actin-spectrin cortical lattice (CL), and the subsurface cisternae (SSC), limits prestin’s mobility53. It 
is also reported that salicylate, a prestin inhibitor that reversibly alters the SSC54, can increase prestin’s mobility in 
the presence Mβ CD53. Although the degree to which the OHC’s trilaminate structure depends on prestin is debat-
able53,55, it remains possible that the CL or SSC contribute to HPβ CD-induced ototoxicity. Further investigation is 
required to fully elucidate how depletion of the cholesterol from the prestin-enriched LM induces cell death. The 
rapidity of this effect is consistent with a recent report56 showing that antioxidants do not protect OHCs against 
HPβ CD toxicity, suggesting that cell death may not involve generation of ROS and apoptotic signaling events.
It is curious that the preservation of OHCs in HPβ CD-treated prestin-KO cochleae was not statistically signif-
icant in the apical region but was limited to the high-frequency basal region (Fig. 1a,b), where NPC1 patients also 
Figure 3. Cholesterol staining of cochleae from WT- and prestin-KO mice. Saline-treated WT- and 
prestin-KO cochleae (as in Fig. 1) were stained with TNM-fluorescein (TNM-FL) and imaged. (a) Single plane 
image at the cuticular plate (XY view, “Cuticular plate”) and (b) along the lateral wall (XY view, “middle”). 
Both WT and KO cochleae show similar cholesterol staining (green) for all rows of OHCs at the cuticular plate. 
(c) Radial view of the z-stack images. Unlike the KO, staining was not observed on the lateral walls of OHCs 
from WT cochlea (XZ view, “OHC-2”, white arrowheads). Red, anti-oncomodulin; Green, TNM-FL. Scale 
bars, 5 μ m.
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experience impairment57. This observation indicates that factors in addition to prestin are likely involved, as choles-
terol can influence a variety of biological processes by modulating various membrane proteins. Coincidentally, effer-
ent nerve innervation is the highest in the middle region where OHC death occurred in both WT and prestin-KO 
cochleae58, raising the possibility that changes in the functions of additional proteins may underlie HPβ CD oto-
toxicity. Efferent innervation to OHCs is mediated by Ca2+ entry through α 9/α 10-nicotinic receptors, followed by 
the activation of small-conductance (SK2) and the voltage- and Ca2+ -activated large conductance potassium (BK) 
channels59. Although the distribution of α 9/α 10-nicotinic receptors along the length of the cochlea is not clear, SK2 
channels and BK channels are not evenly distributed, i.e., high expression is only found in apical and middle coch-
lear turns59. Intriguingly, both nicotinic acetylcholine receptors and BK channels are cholesterol-binding proteins, 
and their functions are regulated in part by cholesterol2. In addition, voltage-gated Ca2+ channels (VGCC) and 
BK channels in chicken hair cells are reported to be sensitive to cholesterol depletion by Mβ CD60, suggesting that 
increased influx of Ca2+ could result in excitotoxicity and cell death. Although it is not clear whether innervation 
densities or channel distributions are altered in prestin-KO mice, it is possible that these factors contribute to OHC 
loss in the apical half of prestin-KO cochleae in response to cholesterol extraction by HPβ CD.
Figure 4. Interaction of prestin and cholesterol. (a) Representative images of Sf9 cells with prestin-GFP 
localizes at the plasma membrane. Scale bar, 10 μ m. (b–e) Non-linear capacitance (NLC) measurements of 
stable Sf9-prestin-GFP cells. (b) Whole-cell recordings of Sf9-prestin-GFP cells were performed in control 
buffer (“Ctrl”), with cholesterol loading (“+ Chol”), and with cholesterol depletion (“− Chol”). (c) Vpkcm. 
Mean ± s.d. are: Ctrl, 40 ± 11 mV (n = 7); + Chol, − 60 ± 19 mV (n = 8); − Chol, 73 ± 12 mV (n = 6). P values 
are as indicated (t-test, compared to Ctrl). (d) alpha. Mean ± s.d. are: Ctrl, 0.039 ± 0.003 mV−1 (n = 7); + Chol, 
0.018 ± 0.004 mV−1 (n = 8); − Chol, 0.037 ± 0.004 mV−1 (n = 6). P values are as indicated (t-test, compared to 
Ctrl). (e) Charge density. Mean ± s.d. are: Ctrl, 5.7 ± 2.8 fC/pF (n = 7); + Chol, 5.9 ± 1.1 fC/pF (n = 8); − Chol, 
7.9 ± 3.7 fC/pF (n = 6). P values are as indicated (t-test, compared to Ctrl). (f) Live-cell TIRF imaging of Sf9-
prestin-GFP cells with cholesterol manipulation. Sf9-prestin-GFP cells were either grown in control media 
(“Ctrl”), in media supplemented with 5 mM Mβ CD (“− Chol”), or 5 mM Mβ CD saturated with cholesterol 
(“Chol”) for 1 h and observed under TIRF microscopy. Scale bars, 5 μ m. (g) Cholesterol pull-down assay of Sf9-
prestin-GFP cells. Cell lysates containing membrane fractions from stable Sf9-prestin-GFP cells were incubated 
with unconjugated control beads or cholesterol-conjugated beads, separated on SDS-PAGE, and probed with 
anti-GFP. Prestin-GFP is pulled-down with cholesterol-conjugated beads but not with unconjugated beads 
(n = 5, p = 0.0059, t-test). Lanes 1, Unconjugated beads; 2, Cholesterol-conjugated beads; 3, Cholesterol-
conjugated beads with addition of exogenous free cholesterol.
www.nature.com/scientificreports/
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HPβ CD is the only promising drug for ameliorating the neurodegenerative phenotype in NPC1 patients. It 
is, therefore, important to elucidate mechanisms of ototoxicity to avoid further hearing impairment in afflicted 
individuals. Recent attempts in minimizing adverse effects of β -CDs include specific targeting of HPβ CD to lys-
osomes by tethering the cyclodextrins to biocleavable polyrotaxanes (HE-SS-PRX)61. Although in vitro studies 
show reduced cytotoxicity by preventing β -CDs from targeting the plasma membrane, it is concerning that cel-
lular access of HE-SS-PRX depends on uptake via endocytic pathways. It, therefore, remains to be seen whether 
HE-SS-PRX can maintain its efficacy without causing toxicity to OHCs in vivo. These complications relate to the 
fact that HPβ CD does not cross the blood-brain barrier62, with the result that current treatment involves direct 
administration to CSF. Since OHCs are bathed in perilymph, which is derived from CSF, it may be difficult to 
avoid damage to OHCs with the current drug-delivering strategies. Additional study is required before we are able 
to develop improved HPβ CD-based therapies to minimize ototoxicity in NPC1 patients.
Methods
Animals. All experimental procedures were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals by NIH, and were approved by Northwestern University’s Animal Care and Use Committee. 
Details on the generation and characterization of prestin knockout (KO) mice is described elsewhere28. In order 
to minimize OHC death in mice lacking prestin38, the prestin KO mice were backcrossed to the FVB strain for 
8 generations (N8). This strain is known to have excellent high-frequency hearing well into adulthood63. Prestin 
wild-type (WT) and KO mice on the FVB background were obtained by Het x Het breeding.
HPβCD treatment and in vivo physiology. After weaning WT and prestin-KO mice were injected with 
0.9% NaCl or 8000 mg/kg HPβ CD dissolved in 0.9% NaCl (Sigma, H107) subcutaneously as described previ-
ously10. Distortion product otoacoustic emissions (DPOAEs) were measured by presenting the two stimulating 
primaries each at 70 dB SPL and for a frequency ratio of f2/f1 = 1.2. Auditory brainstem responses (ABR) were 
also collected to document the output of the cochlea, as well as subsequent neural processing in the brainstem. 
For these recordings, subcutaneous electrodes were inserted at the vertex and the mastoid with each response 
measured relative to the indifferent electrode inserted at the opposite shoulder/neck region. Calibration was 
performed quasi-free field as reported previously64. Thresholds were determined by noting the signal level where 
the ABR waveform disappeared into the noise. Because the number of averages increased as signal level decreased 
(5 dB step size), the noise level was ~0.2 microvolts. Further details on how these recordings are made appear in 
a previous publication65.
Tissue processing and immunostaining. Mice were cardiac perfused with 4% paraformaldehyde and 
cochleae extracted at 7 days post treatment unless otherwise noted. After post-fixation and decalcification, coch-
leae were dissected following the Eaton-Peabody Laboratory cochlear dissection protocol66. For immunostain-
ing, anti-prestin67 and anti-oncomodulin (Santa Cruz) antibodies were used. Secondary antibodies include goat 
anti-rabbit Alexa Fluor 488 and donkey anti-goat Alexa Fluor 488 (Molecular Probes). For cholesterol staining, 
cochlear sections were incubated with 1 μ M TNM-FL33 for 3 days at 4 °C without permeabilization. Stained coch-
lear sections were mounted onto slides using Dako fluorescent mounting medium (DAKO).
Imaging and anatomical measurements. Images were captured on a Nikon C2+ or A1R confocal 
microscope with Plan Fluor 10X and Plan Apo 20X objectives (Nikon) controlled by NIS Element software. For 
TNM imaging, a Plan Apo 60X oil objective (Nikon) was used. Z-stack images were taken with 0.4 μ m inter-
vals and 3D images reconstructed using NIS Element software. Basilar membrane length was measured using 
ImageJ, and the numbers of remaining OHCs determined. A mouse cochlear place-frequency map68 was used to 
Figure 5. In vitro analysis of HPβCD-treated OHCs. (a) Time-lapse images of HPβ CD-treated WT OHCs. 
Isolated OHCs from a WT-control mouse were treated with 1 mM HPβ CD and observed under microscopy. 
OHCs rapidly shorten upon addition of HPβ CD. Scale bars, 5 μ m. (b) HPβ CD treatment of an isolated OC 
from a WT mouse treated with 10 mM HPβ CD. The initial image (t = 0, before the addition of HPβ CD) is 
shown. Red asterisks (*) indicate cells that ruptured during the duration of time-lapse recording. (c) HPβ CD 
treatment of an isolated OC from a prestin-KO mouse treated with 10 mM HPβ CD. The initial image (t = 0, 
before the addition of HPβ CD) is shown. Red asterisks (*) indicate cells that ruptured during the duration of 
time-lapse recording; white asterisks are OHCs that seem to have swollen but not ruptured.
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determine the corresponding frequencies. An Andor XDI Revolution microscope with Apo TIRF 100X oil objec-
tive (Nikon) was used for TIRF imaging.
Plasmids. To generate pIZ-gPres-ceGFP, WT gerbil prestin (gPrestin) with C-terminal EGFP tag was ampli-
fied from gPrestin-GFP69, and cloned into a pIZ/V5-His vector (Invitrogen) using SpeI and XhoI.
Cell Line and cell culture. Sf9 cells (Invitrogen) were maintained in Sf-900 III SFM supplemented with 
5% fetal bovine serum (Gibco) and 1X antibiotic antimycotic solution (Sigma). To generate stable Sf9 cells with 
WT gPrestin, Sf9 cells were transfected with pIZ-gPres-ceGFP using Effectene (Qiagen), and selected with 
1 μ g/μ l zeocin (Invitrogen). A single clone was chosen to establish the stable cell line. The tetracycline-inducible 
WT-gPrestin stable HEK293 cell line (293-TRxST-gPrestin-YFP4TOmycHisC) was a generous gift from Drs. 
Santo-Sacchi and Navaratnam. Growth conditions and induction of the cell line were defined previously47. For 
transient transfections of Sf9 and HEK293T cells with prestin constructs, Effectene (Qiagen) and jetPRIME 
(Polyplus) were used according to the manufacture’s instructions.
Nonlinear capacitance (NLC) measurements. Whole-cell recordings were performed at room temper-
ature using the Axopatch 200 A amplifier (Molecular Devices, CA). Recording pipettes were pulled from borosil-
icate glass to achieve initial bath resistances averaging ~3 MΩ. Intracellular pressure was kept at 0 mmHg during 
recording. Recording pipettes were filled with an intracellular solution containing (mM): 140 CsCl, 2 MgCl2, 10 
EGTA, and 10 HEPES (pH 7.3). Cells were bathed in an extracellular solution containing (mM): 120 NaCl, 20 
TEA-Cl, 2 CoCl2, 2 MgCl2, 10 HEPES (pH 7.3). Osmolarity was adjusted to 310 mmol/kg with glucose. NLC was 
measured using a sinusoidal voltage stimulus (2.5-Hz, 120 or 150 mV amplitude) superimposed with two higher 
frequency stimuli (391 and 781 Hz, 10 mV amplitude)70. Data were collected by jClamp (SciSoft Company, New 
Haven, CT), and NLC determined as described previously70. For cholesterol loading and depletion, 5 mM Mβ CD 
was used with or without a saturating amount of cholesterol.
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where α is the slope factor of the voltage-dependence of charge transfer, Qmax is the maximum charge transfer, 
Vm is the membrane potential, Vpkcm is the voltage at which the maximum charge movement is attained, and Clin 
is the linear capacitance70.
Preparation of Sf9 cell lysates. Sf9 cells stably expressing WT-gPrestin were collected and washed once 
in PBS. Cell pellets were first resuspended in wash buffer (50 mM Tris-Cl buffer (pH 7.4), 1X protease inhibitor 
cocktail (Sigma, P8849) and 1 mM PMSF (Sigma, P7626)), and incubated on ice for 30 min. Cells were then 
homogenized, and spun down at 700 g for 10 min at 4 °C. Supernatants were then transferred to a fresh tube, 
and spun down at 10,000 g for 30 min at 4 °C. The total membrane fraction of Sf9 cells (pellets) were dissolved in 
extraction buffer (50 mM Tris-Cl, pH 7.4, 50 mM NaCl, 25 mM n-dodecyl β -d-maltoside (DDM), 1 mM EGTA, 
1X protease inhibitor cocktail, and 1 mM PMSF) at room temperature for 1 h, and centrifuged at 16,000 g for 
30 min at room temperature. Supernatants containing gPrestin-GFP were used for the cholesterol binding assay.
Cholesterol binding assay. Preparation of cholesterol beads was based on a previous report45,46 and the 
manufacturer’s instructions. CarboxyLink coupling gel (Thermo Scientific) was washed in 30% 1,4-dioxane 
(Fisher) and then in 100% dioxane. Cholesteryl hemisuccinate (Sigma, C6512) was dissolved in 100% dioxane, 
and immobilized on a pre-washed CarboxyLink coupling gel in the presence of N,N’-dicyclohexylcarbodiimide 
(DCC; Thermo Scientific, 20320) at room temperature for 4 hours. The cholesterol-beads were then washed 
twice each in 100% dioxane, 30% dioxane, and then stored in PBS. At the same time, pre-washed CarboxyLink 
coupling gel was processed without cholesteryl hemisuccinate to serve as a control for non-specific binding. 
Cholesterol-beads or unconjugated control beads were mixed with cell lysates containing membrane fractions 
isolated from stable Sf9 cells (described above) in the presence or absence of 1 mM cholesterol, and incubated for 
1 h at room temperature. The reaction mix was then centrifuged and washed 5 times with 50 mM Tris, and eluted 
with 2X Laemmli Sample Buffer (BioRad) at room temperature for 30 min. Eluates were analyzed by Western 
blotting.
Western blotting. For detection of gPrestin expressed in Sf9 cells, samples were separated on 4–20% gradi-
ent Mini-Protein precast gels (BioRad), transferred to 0.45 μ m nitrocellulose membranes (BioRad) and probed 
with 1:5000 dilutions of anti-V5 antibodies (Invitrogen) followed by 1:5000 dilutions of goat anti-mouse-HRP 
antibodies (Jackson Laboratory). For detection of gPrestin expressed in HEK293T cells, anti-GFP (Rockland) and 
anti-chicken-HRP (Jackson Laboratory) antibodies were used.
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